Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Respiratory syncytial virus: seasonal data for regions of Florida and implications for palivizumab Bauman J; Eggleston M; Oquist N; Malinoski FSouth Med J 2007[Jul]; 100 (7): 669-76BACKGROUND: The aims of this study are to define the length of the respiratory syncytial virus (RSV) season throughout Florida and evaluate the American Academy of Pediatrics (AAP) guidelines on the administration of palivizumab in light of the Florida data. METHODS: We retrospectively analyzed four seasons of monthly RSV surveillance data housed on the Florida Department of Health website for regional trends in RSV outbreaks. RESULTS: RSV circulated year round in Florida, with December being the peak month for RSV activity statewide. Regional virology data showed consistent patterns throughout the observation period, and all regions experienced widespread RSV activity for at least seven months of the year. The southeast region experienced the longest RSV seasons (10-12 mo), with year round outbreaks observed during 2000 to 2001 and 2001 to 2002. CONCLUSIONS: Local RSV surveillance provides meaningful data to guide decisions on the administration of palivizumab. Reliance on current AAP guidelines for RSV prophylaxis would result in under-protection of at-risk children in all regions within the state of Florida.|*Respiratory Syncytial Virus Infections/epidemiology/immunology/prevention & control[MESH]|*Seasons[MESH]|*Sentinel Surveillance[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Antiviral Agents/therapeutic use[MESH]|Child, Preschool[MESH]|Florida/epidemiology[MESH]|Humans[MESH]|Immunization, Passive/*methods[MESH]|Infant[MESH]|Palivizumab[MESH]|Practice Guidelines as Topic[MESH]|Respiratory Syncytial Viruses/*immunology[MESH]|Retrospective Studies[MESH] |
